European Commission investigates Aspen for ‘price gouging’

17-05-2017

The European Commission has opened an investigation into multinational company Aspen Pharma over the price of five cancer drugs.


European Commission, Aspen Pharma, anti-trust, cancer drugs, competition, patent

LSIPR